Telomere proteins, called shelterins, are an important structural and functional element protecting the ends of chromosomes of eukaryotic cells, including human ones. The proper functioning of these proteins ensures proper cell division and protects the ends of telomeric DNA from damage. The telomeric proteins include: TRF1 and TRF2 proteins that play a structural role. They form homodimers that bind in a specific way to telomeric DNA made of tandem repeats of 7 nucleotides rich in G. These proteins additionally interact with the TIN2 protein, which is a linker to the remaining structural elements of the telomeric complex. In cancer cells, the TRF1 and TRF2 proteins are of particular importance because the telomeres in these cells are shorter and any disruption of the telomeric protein complex is lethal to these cells. Therefore, it has been postulated for several years that TRF1 and TRF2 proteins may be a new molecular target in anticancer chemotherapy. Our project is a continuation of the earlier STRATEGMED project, in which we have already found leading compounds that block the interaction of TRF1 and TRF2 proteins with the TIN2 protein. These are two small molecule compounds already covered by a patent application. In the current project, we would like to extend this research and find derivatives of these compounds with even better chemotherapeutic parameters. The project would involve the in silico design of new derivatives based on already known lead molecules. Then, these compounds would be synthesized and their properties would be determined in vitro (including blocking the TRF1/2-TIN2 interaction) and in vivo (biological effects in cell cultures). The project would be implemented in cooperation with the University of Gdańsk. The implementation of the project will allow research to be carried out in a very modern and important subject, in which the applying team has already achieved achievements and is one of the world's pioneers. The results of the project will have a chance to be published in prestigious international journals. In the longer term, they may lead to a patent and commercialization.
Details
- Financial Program Name:
- OPUS
- Organization:
- Narodowe Centrum Nauki (NCN) (National Science Centre)
- Realisation period:
- 2024-01-29 - 2028-01-28
- Project manager:
- prof. dr hab. inż. Maciej Bagiński
- Realised in:
- Department of Pharmaceutical Technology and Biochemistry
- External institutions
participating in project: -
- Uniwersytet Gdański (Poland)
- Request type:
- National Research Programmes
- Domestic:
- Domestic project
- Verified by:
- Gdańsk University of Technology
seen 62 times